ZLDPF is no longer actively traded. Data shown reflects verified historical relationships.
1Suppliers
2Customers
1Debt Items
15Related Chains

Zealand Pharma A/S Suppliers

TickerNameConfidenceEvidence
IRWD Ironwood Pharmaceuticals, Inc. 72% Reciprocal relationship from IRWD graph: products and to leverage our existing capabilities to develop and commercialize these products in the U.S. We have pursued a partnering strategy for commercia…

Zealand Pharma A/S Customers

TickerNameConfidenceEvidence
IRWD Ironwood Pharmaceuticals, Inc. 72% Reciprocal relationship from IRWD graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD…
PTGX Protagonist Therapeutics, Inc. 72% Reciprocal relationship from PTGX graph: s and Other Commitments In the normal course of business, we enter into agreements with contract service providers to assist in the performance of our researc…

Zealand Pharma A/S Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZLDPF-DEBT Debt stack $64.4M 90% Market cache reports total debt of $64.4M.

Zealand Pharma A/S Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zealand Pharma A/S.

Zealand Pharma A/S Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Zealand Pharma A/S.

Zealand Pharma A/S Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ADCT ADC Therapeutics SA 100.00 2
ACAD ACADIA Pharmaceuticals Inc. 100.00 2
PTGX Protagonist Therapeutics, Inc. 100.00 1 ['customer']
IRWD Ironwood Pharmaceuticals, Inc. 100.00 1 ['customer', 'supplier']
GNMSF Genmab A/S 100.00 2
MLTX MoonLake Immunotherapeutics 50.00 2
NEUP Neuphoria Therapeutics Inc. 50.00 2
RANI Rani Therapeutics Holdings, Inc. 50.00 2
JNJ Johnson & Johnson 50.00 2
AZN AstraZeneca PLC 50.00 2
ORANY ORANGE 50.00 2
ABBV AbbVie Inc. 50.00 2
JAGX Jaguar Health, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
GHRS GH Research PLC 36.29 1 ['spend']